Mounjaro Just Got a Promotion. Novo Nordisk Should Be Nervous.

One wrinkle worth noting: GI side effects (think nausea, vomiting, the usual GLP-1 complaints) were more common with tirzepatide and led to more patients dropping out of the trial.

Why This Is Really About Novo Nordisk

To understand why this label matters commercially, you need to understand the scoreboard. Novo Nordisk's semaglutide (Ozempic for diabetes, Wegovy for obesity) has been the undisputed king of the incretin class. Its SELECT trial showed semaglutide reduced MACE in adults with obesity and established heart disease by 20% versus placebo, with a hazard ratio of 0.80.

On paper, that's a more impressive number than tirzepatide's 0.92 against an active comparator. But head-to-head comparisons between the two trials are like comparing a tennis player's record on clay versus grass: the conditions are different, and the opponents aren't the same.

What does matter is the label. Before this approval, Novo could tell doctors and payers: "Only semaglutide has a cardiovascular indication among the newer incretins." That talking point just evaporated. Lilly closed a gap that had been one of Novo's strongest selling points, and it did so with a drug that arguably offers better weight loss and blood sugar control through its dual GIP/GLP-1 mechanism.

The incretin wars are now a genuine two-horse race, and the finish line keeps moving further out.

A Brief History of Heart Labels

Cardiovascular labels in diabetes drugs have a fascinating origin story rooted in scandal. After the rosiglitazone scare in the late 2000s, the FDA started requiring new diabetes drugs to prove they don't cause excess cardiovascular harm. That mandate, issued in 2008, forced companies to run massive outcome trials.

Something unexpected happened: some of those trials showed that certain drugs actually helped hearts, not just avoided hurting them. Empagliflozin (Jardiance) earned the first cardiovascular-benefit label for a diabetes drug in 2016. Liraglutide followed in 2017 with the first GLP-1 cardiovascular label. Injectable semaglutide joined that club in 2020.

Tirzepatide's 2026 approval continues this evolution. What started as a safety requirement has become a launchpad for blockbuster commercial claims. The CVOT framework went from being a regulatory hurdle to a competitive weapon.

Follow the Money

Lilly's tirzepatide franchise is already a cash machine. In Q1 2026 alone, Mounjaro pulled in $8.66 billion in sales. Its obesity-branded sibling Zepbound added another $4.16 billion. Those numbers were growing even as Lilly cut self-pay Zepbound vial prices to $299 for the lowest dose, a move designed to fend off compounded knockoffs and expand the patient pool.

The cardiovascular label should make that machine even more productive. Payer coverage for diabetes drugs with proven heart benefits tends to be broader and stickier than coverage for drugs positioned purely on blood sugar control. Insurers think in terms of downstream costs: if a drug prevents heart attacks, it potentially saves them hundreds of thousands of dollars per avoided hospitalization.

That said, tirzepatide still faces affordability headwinds. One cost-effectiveness analysis estimated the drug would need a 30.5% additional discount from its estimated net price to hit the commonly used $100,000 per quality-adjusted life year threshold. And for Zepbound specifically (the obesity brand), only 28% of commercial plans currently provide coverage. A cardiovascular label for Mounjaro helps the diabetes side of the business more directly; whether it trickles over to improve Zepbound's coverage story remains an open question.

What Happens Next

The GLP-1 competitive landscape has officially entered its second act. The first act was about proving these drugs work for weight loss and blood sugar. The second act is about proving they protect organs: hearts, kidneys, livers. Every major incretin player is now racing to stack indications like frequent flyer miles.

For Novo Nordisk, the response is clear: defend semaglutide's broader evidence base across obesity, heart failure with preserved ejection fraction (a type of heart failure where the heart pumps normally but is still too stiff), chronic kidney disease, and peripheral artery disease. The depth of semaglutide's clinical program remains formidable.

For Lilly, the strategy is equally obvious: use the new cardiovascular label to pry open formulary positions, gain preferred status with payers, and keep building the case that dual agonism is the superior mechanism.

The real winner? Patients with type 2 diabetes who now have two major drug families, each with proven cardiovascular benefits, competing fiercely for their prescription. In a market that sometimes feels rigged against the consumer, competition like this is genuinely good news.

One Shot to Rewrite Your Cholesterol Forever

CRISPR Therapeutics just showed that a single IV infusion can slash cholesterol and triglycerides for at least a year by permanently editing a gene in liver cells. The one-year Phase 1a data for CTX310 are stunning, but the jump from 15 patients to the real world is where things get interesting.